Trogenix announced the completion of its Series A financing, raising $95 million (£70 million) to advance its pipeline of cancer therapies across multiple aggressive solid tumors into the clinic.
The investment will accelerate the company’s lead program in glioblastoma and follow-on program in colorectal cancer liver metastases through the clinic, advances its pipeline in liver and lung cancers, and further enhances the company’s proprietary Odysseus platform.
Trogenix’s lead program, in glioblastoma, one of the most aggressive and treatment-resistant brain cancers, is advancing toward clinical trials with first patient dosing anticipated in Q1 2026.
The Series A financing was led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons, the Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital, as well as undisclosed private investors.
Trogenix’ technology combines the dual power of cancer cell killing and immune stimulation, delivered via a Trojan Horse approach that reawakens the immune system to provide long-term protection against tumor recurrence. Using proven AAV vectors, the company’s proprietary Synthetic Super-Enhancers (SSEs) are delivered directly to tumor cells without detection. The SSEs enable precision in gene control, effectively revealing cancer to the body’s immune system and killing tumor cells.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!